<DOC>
	<DOCNO>NCT01627223</DOCNO>
	<brief_summary>This prospective , observational , open-label , 2-arm , parallel , multi-center study . Patients HBV-associated severe acute exacerbation treatment NRTI ( lamivudine entecavir ) medically recommend screened eligibility . To target 74 evaluable subject , approximately 82 patient recruited trial . After enrollment , eligible subject randomly assign one antiviral treatment . - Cohort 1 : Lamivudine 100 mg p.o . q.d . - Cohort 2 : Entecavir 0.5 mg p.o . q.d . This process stratify prolonged PT , &lt; 4 sec / 4-6 sec / &gt; 6 sec . Both lamivudine entecavir take daily first dose observational drug administer Day 1 . The observational period individual subject 12 week ; however , treatment could continue end study base physician 's clinical judgment . The efficacy safety data collect baseline , 3 , 5 , 8 , 15 , 22 , 29 , 85 , 180 day initiation antiviral treatment . All assessment conduct base routine practice hospital . Only analysis HBV DNA anti-HDV perform central lab . For patient willing provide residual sample HBV DNA assessment , blood sample preserve appropriately . All AE ( ) SAE follow resolution event consider stable .</brief_summary>
	<brief_title>Comparison Between Lamivudine Entecavir Treatment Spontaneous Severe Acute Exacerbation</brief_title>
	<detailed_description>The study compare treatment response lamivudine entecavir patient spontaneous severe acute exacerbation chronic hepatitis B . 1 . Primary objective : • To compare overall survival ( OS ) rate observational period lamivudine entecavir therapy . 2 . Secondary objective : 1 . To compare change baseline HBV DNA level visit lamivudine entecavir therapy . 2 . To compare proportion subject ≥ 2 log10 decline baseline HBV DNA level visit lamivudine entecavir therapy . 3 . To compare change baseline ALT AST level visit lamivudine entecavir therapy . 4 . To compare proportion subject prolong prothrombin time ( PT ) visit lamivudine entecavir therapy . 5 . To compare change baseline bilirubin level visit lamivudine entecavir therapy . 6 . To compare transplantation-free survival rate observational period lamivudine entecavir therapy . 7 . To assess safety lamivudine entecavir treatment patient HBV-associated severe acute exacerbation . Statistical method ( ) safety/efficacy evaluation : 1 . The major analysis perform accord principal intent-to-treat population ; safety evaluation perform accord safety population . 2 . For primary endpoint , time event analyze Kaplan-Meier method summarize number observation , number censor , median time point estimate 95 % CI median . 3 . Secondary efficacy endpoint : 1 . Change baseline HBV DNA level visit 2 . Proportion subject HBV DNA response* visit - Defined ≥ 2 log10 decline baseline HBV DNA level . 3 . Change baseline ALT level visit 4 . Change baseline AST level visit 5 . Proportion subject prolong PT* visit - PT visit also assess . 6 . Change baseline bilirubin level visit 7 . Transplantation-free survival rate observational period Continuous variable analyze use two-sample t-test/ Wilcoxon Rank Sum test , categorical variable analyze Chi-squared/ Fishers ' exact test . Descriptive statistic include mean , standard deviation , median , minimum , maximum , 95 % confidence interval also present . Categorical variable summarize count percentage frequency table . In addition , time event analyze Kaplan-Meier method . ( 4 ) The summary result laboratory baseline end study visit , change baseline end study visit summarize descriptive statistic pair t-test used significant level 0.05 . ( 5 ) Adverse event cod MedDRA summary frequency table adverse event provide . The severity relationship study medication adverse event summarize well . Furthermore , serious adverse event occur , brief summary serious adverse event describe listed table . ( 6 ) All statistical test two-side evaluate 0.05 level significance .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Male female ≥ 20 year age 2 . HBsAg carrier spontaneously severe acute exacerbation treatment nucleoside nucleotide reverse transcriptase inhibitor ( NRTI ) lamivudine entecavir medically recommended 3 . Patients fulfill follow criterion screen : document HBsAg positive least 6 month antiHBc IgM negative HBV DNA ≥ 2,000 IU/mL* * The blood sample collect screen visit , criterion check obtain lab result . For patient fulfill criterion , enrol immediately . total bilirubin ≥ 2 mg/dL prolong prothrombin time ( PT ) ≥ 3 sec serum ALT ≥ 10 x ULN 4 . Patient sufficient renal function define SCr ≤ 1.5 x ULN ClCr ≥ 50 mL/min 5 . Willing able sign write informed consent 1 . Female pregnant/lactating 2 . Patient underlie liver cirrhosis classify ChildPugh class B C 3 . Patients document hepatitis A virus ( HAV ) , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) human immunodeficiency virus ( HIV ) coinfection 4 . Patients uncontrolled malignancy 5 . History presence alcohol substance abuse within 1 year prior initiation NRTI treatment 6 . History hypersensitivity ingredient observational drug ( Zeffix® Baraclude® ) 7 . Current use medicine may induce hepatotoxicity 8 . Use antiviral therapy HBV , interferonα ( IFNα ) nucleotide/nucleoside analogue , within 6 month prior initiation NRTI treatment exposure treatment 3 month 9 . Use chemotherapy immunosuppressive agent within 12 month prior initiation NRTI treatment 10 . Use investigational product , include drug invasive medical device , within 4 week prior initiation NRTI treatment 11 . Patient medical psychiatric condition , include presence significant abnormal laboratory value , consider suitable study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Spontaneous Severe Acute Exacerbation Chronic Hepatitis B</keyword>
	<keyword>Lamivudine ( Zeffix® )</keyword>
	<keyword>Entecavir ( Baraclude® )</keyword>
</DOC>